167 related articles for article (PubMed ID: 1349891)
1. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.
Hofmann J; Wolf A; Spitaler M; Böck G; Drach J; Ludescher C; Grunicke H
J Cancer Res Clin Oncol; 1992; 118(5):361-6. PubMed ID: 1349891
[TBL] [Abstract][Full Text] [Related]
2. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
Höllt V; Kouba M; Dietel M; Vogt G
Biochem Pharmacol; 1992 Jun; 43(12):2601-8. PubMed ID: 1352973
[TBL] [Abstract][Full Text] [Related]
3. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Dietel M; Boss H; Reymann A; Pest S; Seidel A
J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
[TBL] [Abstract][Full Text] [Related]
4. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein.
Cornwell MM; Pastan I; Gottesman MM
J Biol Chem; 1987 Feb; 262(5):2166-70. PubMed ID: 2434476
[TBL] [Abstract][Full Text] [Related]
5. Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.
Roller E; Klumpp B; Krause J; Eichelbaum M; Schumacher K
Cancer Chemother Pharmacol; 1993; 32(2):151-5. PubMed ID: 8097969
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of the Ca2+/calmodulin antagonist B859-35 and the Ca(2+)-channel blocker verapamil on human lung cancer cell lines.
Schüller HM; Orloff M; Reznik GK
Carcinogenesis; 1991 Dec; 12(12):2301-3. PubMed ID: 1747931
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
Pascaud C; Garrigos M; Orlowski S
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
[TBL] [Abstract][Full Text] [Related]
8. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.
Shudo N; Mizoguchi T; Kiyosue T; Arita M; Yoshimura A; Seto K; Sakoda R; Akiyama S
Cancer Res; 1990 May; 50(10):3055-61. PubMed ID: 1970752
[TBL] [Abstract][Full Text] [Related]
9. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
10. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
Hill BT; Hosking LK
Cancer Chemother Pharmacol; 1994; 33(4):317-24. PubMed ID: 8281626
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
12. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35.
Uberall F; Maly K; Egle A; Doppler W; Hofmann J; Grunicke HH
Cancer Res; 1991 Nov; 51(21):5821-5. PubMed ID: 1718584
[TBL] [Abstract][Full Text] [Related]
16. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.
Horio M; Lovelace E; Pastan I; Gottesman MM
Biochim Biophys Acta; 1991 Jan; 1061(1):106-10. PubMed ID: 1671642
[TBL] [Abstract][Full Text] [Related]
17. Rapid stimulation of rhodamine 123 efflux from multidrug-resistant KB cells by progesterone.
Jancis EM; Chen HX; Carbone R; Hochberg RB; Dannies PS
Biochem Pharmacol; 1993 Nov; 46(9):1613-9. PubMed ID: 7902090
[TBL] [Abstract][Full Text] [Related]
18. The interaction of phenylalkylamine calcium channel blockers with the 1,4-dihydropyridine binding site.
Zobrist RH; Giacomini KM; Nelson WL; Giacomini JC
J Mol Cell Cardiol; 1986 Sep; 18(9):963-74. PubMed ID: 3783730
[TBL] [Abstract][Full Text] [Related]
19. Modulation of glycine responses by dihydropyridines and verapamil in rat spinal neurons.
Chesnoy-Marchais D; Cathala L
Eur J Neurosci; 2001 Jun; 13(12):2195-204. PubMed ID: 11454022
[TBL] [Abstract][Full Text] [Related]
20. B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance.
Hofmann J; Ueberall F; Egle A; Grunicke H
Int J Cancer; 1991 Apr; 47(6):870-4. PubMed ID: 1849122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
